论文部分内容阅读
目的探讨阿托伐他汀对急性冠脉综合征(ACS)患者血清高敏C反应蛋白(hs-CRP)的影响。方法采用酶联免疫吸附法测定62例CHD患者和20例对照组的hs-CRP水平。同时将ACS患者随机分为常规治疗组和阿托伐他汀治疗组,治疗4周后再次测定血清hs-CRP水平。结果 (1)hs-CRP水平在UAP组、AMI组较SAP组、对照组显著升高(P<0.01)。(2)4周后,阿托伐他汀治疗组血清hs-CRP水平较治疗前明显降低,且较常规治疗组治疗4周后亦有显著降低(P<0.05)。结论阿托伐他汀在ACS早期治疗中可降低ACS患者hs-CRP水平,减少动脉粥样硬化斑块的炎症反应,具有稳定斑块的作用。
Objective To investigate the effect of atorvastatin on serum high-sensitivity C-reactive protein (hs-CRP) in patients with acute coronary syndrome (ACS). Methods The levels of hs-CRP in 62 CHD patients and 20 control subjects were determined by enzyme-linked immunosorbent assay. At the same time ACS patients were randomly divided into conventional treatment group and atorvastatin treatment group, after 4 weeks of treatment, serum hs-CRP level was measured again. Results (1) The levels of hs-CRP in UAP group and AMI group were significantly higher than those in SAP group and control group (P <0.01). (2) After 4 weeks, serum hs-CRP levels in atorvastatin group were significantly lower than those before treatment, and were significantly lower than those in the conventional treatment group after 4 weeks of treatment (P <0.05). Conclusions Atorvastatin can reduce the level of hs-CRP, reduce the inflammatory reaction of atherosclerotic plaque and stabilize the plaque in the early stage of ACS.